share_log

UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema

UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema

UNITY Biotechnology 宣佈延長評估糖尿病黃斑水腫患者的 UBX1325 ASPIRE 2b 期臨床研究
Benzinga ·  04/23 20:02

UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema

UNITY Biotechnology 宣佈延長評估糖尿病黃斑水腫患者的 UBX1325 ASPIRE 2b 期臨床研究

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論